Evommune Licenses China Originated VAV1 Degrader
Evommune entered an ex-Greater-China license for Hinova’s oral VAV1 molecular glue degrader EVO570 on November 4. The SEC filing specifies $20 million cash and pre-funded warrants valued at $10 million as upfront consideration, plus…
